Single blood test could provide more information about cancer

A single blood test could soon offer a more comprehensive view of cancer than current methods. Researchers at Karolinska Institutet have reviewed the development of a technique called multifeature sequencing-based liquid biopsy, which can analyze multiple biological signals from a single blood sample. Currently, doctors use liquid biopsies to detect tumor material in the blood, providing a less invasive alternative to traditional tissue samples and allowing them to monitor disease progression over time.

The new approach, called multifeature sequencing-based liquid biopsy (MSLB), combines various molecular signals into one analysis. These signals may include free DNA and RNA in the blood, changes in the genome's structure, and chemical markers. By examining several biological markers simultaneously, MSLB could provide a broader understanding of the tumor's characteristics compared to studying each signal separately.

Early research studies using combinations of DNA methylation, fragment size, and chromosomal changes in blood have shown promise for early cancer detection and monitoring the disease over time. Advanced bioinformatics methods and machine learning are used to interpret the vast amounts of data generated by these analyses. However, the technology still faces several challenges, such as studies being conducted on limited patient groups and the need for larger prospective studies to confirm results.

Additionally, the methods are technically complex, and standardized workflows are lacking for quality assurance across different healthcare centers.

Despite these challenges, researchers believe the first clinical applications of MSLB will likely be in monitoring cancer patients, assessing treatment effects, and situations where obtaining repeated tissue samples is difficult. In the long term, this method could offer a more integrated and dynamic picture of cancer development based on a simple blood sample.